Lifecore Biomedical Stock Net Income
| LFCR Stock | 6.65 0.08 1.22% |
Lifecore Biomedical fundamentals help investors to digest information that contributes to Lifecore Biomedical's financial success or failures. It also enables traders to predict the movement of Lifecore Stock. The fundamental analysis module provides a way to measure Lifecore Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lifecore Biomedical stock.
| Last Reported | Projected for Next Year | ||
| Net Income | 8.4 M | 8.8 M | |
| Net Income From Continuing Ops | 8.4 M | 8.8 M | |
| Net Loss | -92 M | -87.4 M | |
| Net Loss | (0.08) | (0.09) | |
| Net Loss | (7.40) | (7.03) |
Lifecore | Net Income |
Lifecore Biomedical Company Net Income Analysis
Lifecore Biomedical's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Lifecore Biomedical Net Income | 9.33 M |
Most of Lifecore Biomedical's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lifecore Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lifecore Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Lifecore Biomedical is extremely important. It helps to project a fair market value of Lifecore Stock properly, considering its historical fundamentals such as Net Income. Since Lifecore Biomedical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lifecore Biomedical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lifecore Biomedical's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Lifecore Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Lifecore Biomedical reported net income of 9.33 M. This is 97.27% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 98.37% higher than that of the company.
Lifecore Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lifecore Biomedical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lifecore Biomedical could also be used in its relative valuation, which is a method of valuing Lifecore Biomedical by comparing valuation metrics of similar companies.Lifecore Biomedical is currently under evaluation in net income category among its peers.
Lifecore Biomedical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lifecore Biomedical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lifecore Biomedical's managers, analysts, and investors.Environmental | Governance | Social |
Lifecore Biomedical Institutional Holders
Institutional Holdings refers to the ownership stake in Lifecore Biomedical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lifecore Biomedical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lifecore Biomedical's value.| Shares | State Street Corp | 2024-12-31 | 375.3 K | Northern Trust Corp | 2024-12-31 | 221.5 K | Tocqueville Asset Management L.p. | 2024-12-31 | 151.7 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 133.2 K | Quinn Opportunity Partners Llc | 2024-12-31 | 127.9 K | Alpha Wave Global Lp | 2024-12-31 | 116.5 K | Ubs Group Ag | 2024-12-31 | 109 K | Boothbay Fund Management, Llc | 2024-12-31 | 87.1 K | Gamco Investors, Inc. Et Al | 86 K | Wynnefield Capital Inc | 2024-12-31 | 4.7 M | Legion Partners Asset Management, Llc | 2024-12-31 | 4.4 M |
Lifecore Fundamentals
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.0247 | ||||
| Profit Margin | (0.11) % | ||||
| Operating Margin | (0.05) % | ||||
| Current Valuation | 365.14 M | ||||
| Shares Outstanding | 37.03 M | ||||
| Shares Owned By Insiders | 4.52 % | ||||
| Shares Owned By Institutions | 73.59 % | ||||
| Number Of Shares Shorted | 2.4 M | ||||
| Price To Book | 15.75 X | ||||
| Price To Sales | 1.86 X | ||||
| Revenue | 128.26 M | ||||
| Gross Profit | 45.64 M | ||||
| EBITDA | 35.6 M | ||||
| Net Income | 9.33 M | ||||
| Total Debt | 130.36 M | ||||
| Book Value Per Share | 0.42 X | ||||
| Cash Flow From Operations | (217 K) | ||||
| Short Ratio | 19.93 X | ||||
| Earnings Per Share | (0.56) X | ||||
| Price To Earnings To Growth | 3.51 X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 524 | ||||
| Beta | 0.97 | ||||
| Market Capitalization | 243.26 M | ||||
| Total Asset | 273.7 M | ||||
| Retained Earnings | (166.52 M) | ||||
| Working Capital | 42.16 M | ||||
| Net Asset | 273.7 M |
About Lifecore Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lifecore Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lifecore Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lifecore Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.